Kopran Limited has submitted a regulatory disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, regarding the closure of a Good Manufacturing Practice (GMP) inspection conducted by the European Union Medicine Authority.
The inspection took place at the company's formulation manufacturing facility located in Khopoli from September 18, 2026 to September 23, 2026. The inspection was successfully concluded with the following outcomes: no critical observations were noted, one major observation was identified, and some minor observations were recorded. Importantly, there were no data integrity related observations during the inspection.
The company is currently in the process of preparing and will submit compliance responses to the EU authorities within a fortnight from October 22, 2026. The disclosure was signed by Sunil Radheyshyam Sodhani, Company Secretary & Compliance Officer (Membership No. FCS 3897) on behalf of Kopran Limited.